Active surveillance for favorable risk prostate cancer: What are the results, and how safe is it?

被引:20
|
作者
Klotz, Laurence [1 ]
机构
[1] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Urol, Toronto, ON M4N 3M5, Canada
关键词
D O I
10.1016/j.semradonc.2007.09.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Active surveillance for favorable risk prostate cancer has become increasingly popular in populations in which prostate cancer screening is widespread because of evidence that prostate cancer screening results in the detection of disease that is not clinically significant in many patients (ie, untreated, would not pose a threat to health). The approach is supported by data showing that patients who fall into the category of clinically insignificant disease can be identified with reasonable accuracy and that patients who are initially classified as low risk who reclassify over time as higher risk and are treated radically are still cured in most cases. This means (1) identifying patients who have a low likelihood of disease progression during their lifetime based on clinical and pathologic features of the disease and patient age and comorbidity, (2) close monitoring over time, (3) reasonable criteria for intervention that will both identify more aggressive disease in a timely fashion and not result in excessive treatment, and (4) meeting the communication challenge to reduce the psychological burden of living with untreated cancer. The results of active surveillance, the criteria for patient selection, and the appropriate triggers for intervention are reviewed. © 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:2 / 6
页数:5
相关论文
共 50 条
  • [1] Active surveillance for favorable-risk prostate cancer: What are the results and how safe is it?
    Laurence Klotz
    [J]. Current Urology Reports, 2007, 8 (5) : 341 - 344
  • [2] Active surveillance for favorable risk prostate cancer: Rationale, risks, and results
    Klotz, Laurence
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2007, 25 (06) : 505 - 509
  • [3] Low Risk-Prostate Cancer: How safe is active Surveillance?
    Knipper, Sophie
    Maurer, Tobias
    [J]. AKTUELLE UROLOGIE, 2021, 52 (02) : 106 - 107
  • [4] Active surveillance for favorable-risk prostate cancer: who, how and why?
    Laurence Klotz
    [J]. Nature Clinical Practice Oncology, 2007, 4 : 692 - 698
  • [5] Active surveillance for favorable-risk prostate cancer: who, how and why?
    Klotz, Laurence
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (12): : 692 - 698
  • [6] Active Surveillance for Favorable Risk Prostate Cancer PRO
    Klotz, Laurence
    [J]. JOURNAL OF UROLOGY, 2009, 182 (06): : 2565 - 2566
  • [7] Active Surveillance for Favorable Risk Prostate Cancer BEWARE THE RISKS
    Parekh, Dipen J.
    [J]. JOURNAL OF UROLOGY, 2009, 182 (06): : 2566 - 2568
  • [8] Contemporary approach to active surveillance for favorable risk prostate cancer
    Klotz, Laurence
    [J]. ASIAN JOURNAL OF UROLOGY, 2019, 6 (02) : 146 - 152
  • [9] Active surveillance in intermediate risk prostate cancer: is it safe?
    Krishnananthan, Nishanth
    Lawrentschuk, Nathan
    [J]. INTERNATIONAL BRAZ J UROL, 2016, 42 (03): : 418 - 421
  • [10] Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study
    Meunier, Matthias
    Eyraud, Remi
    Senechal, Cedric
    Gourtaud, Gilles
    Roux, Virginie
    Lanchon, Cecilia
    Brureau, Laurent
    Blanchet, Pascal
    [J]. JOURNAL OF UROLOGY, 2017, 197 (05): : 1229 - 1235